Filing Flows › Ideaya Biosciences (IDYA) › Stock forecast & fair value
Ideaya Biosciences (IDYA) stock forecast and fair value
Ideaya Biosciences (IDYA) trades at $36.11. 13 analysts' median price target is $51.00 (+41%), from $30.00 to $66.00. Across 15 valuation methods the middle fair value is $9.51 (-74%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| EV/Sales vs peers | $12.90 | $16.36 | $24.10 | -55% |
| EV/Sales vs peers, weighted | $14.99 | $19.68 | $26.38 | -46% |
| Residual income | −$1.48 | −$1.49 | −$1.50 | -104% |
| Analysts' price targets | $30.00 | $51.38 | $66.00 | +42% |
| Path-to-margin DCF | −$3.12 | $0.22 | $3.55 | -99% |
| Path-to-margin DCF, dilution-adjusted | −$2.30 | $0.16 | $2.69 | -100% |
| Exit-multiple (venture) method | $5.54 | $10.25 | $23.51 | -72% |
| EV/Sales vs Rule of 40 (all-company fit) | $9.42 | $11.80 | $18.34 | -67% |
| Survival-weighted value | $1.43 | $3.10 | $4.82 | -91% |
| Stage-weighted value (pre-profit / high growth) | $4.81 | $7.75 | $13.91 | -79% |
Ideaya Biosciences' latest quarter
Ideaya Biosciences, Q3 2026: revenue $10.2M (-95% year over year), net loss $126M, operating cash flow −$93.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for IDYA stock?
The median of 13 analysts' 12-month targets is $51.00, +41% from $36.11; the range is $30.00 to $66.00. The average rating is strong buy.
What is Ideaya Biosciences' fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between −$1.49 and $51.38, with a middle value of $9.51 against a price of $36.11. Each method's assumptions are on the page.
Does Ideaya Biosciences usually beat earnings estimates?
It beat the consensus EPS estimate in 40% of the quarters on record.
Is IDYA stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.